N'ime afọ ndị na-adịbeghị anya, ọgwụgwọ oke ibu na ụdị ọrịa shuga 2 enweela ọganihu mgbanwe. Na-eso GLP-1 agonists nnabata (dịka, Semaglutide) na abụọ agonists (dịka, Tirzepatide),Retatrutide(LY3437943), aatọ agonist(GLP-1, GIP, na ndị na-anabata glucagon), egosila arụmọrụ na-enwetụbeghị ụdị ya. Site na nsonaazụ dị ịrịba ama na mbelata ibu na mmụba nke metabolic, a na-ahụta ya dị ka ọgwụgwọ nwere ike ibute ọrịa metabolic.
Usoro nke Omume
-
GLP-1 nnabata nnabata: Na-eme ka mmepụta insulin dịkwuo elu, na-ebelata agụụ, na-egbu oge ịwụsa afọ.
-
GIP nnabata ọrụNa-akwalite mmetụta na-ebelata glucose nke GLP-1, na-eme ka mmetụta insulin dịkwuo mma.
-
Ntinye ọrụ nnabata glucagon: Na-akwalite mmefu ume na metabolism abụba.
Mmekọrịta nke ndị nnata atọ ndị a na-enye ohere ka Retatrutide karịa ọgwụ ndị dị adị na ma ibu ibu yana njikwa glycemic.
Data nnwale ụlọọgwụ (Nkeji II)
Na aỌnwụnwa nke abụọ nke nwere ndị ọrịa 338 buru ibu / oke ibu, Retatrutide gosipụtara nsonaazụ na-ekwe nkwa nke ukwuu.
Tebụl: Ntụle nke Retatrutide vs. Placebo
| Ọgwụ (mg/izu) | Mbelata ịdị arọ (%) | Mbelata HbA1c (%) | Ihe omume ọjọọ |
|---|---|---|---|
| 1 mg | -7.2% | -0.9% | Ọgbụgbọ, ọgbụgbọ dị nro |
| 4 mg | -12.9% | -1.5% | Ọgbụgbọ, enweghị agụụ |
| 8 mg | -17.3% | -2.0% | GI erughị ala, obere afọ ọsịsa |
| 12 mg | -24.2% | -2.2% | Ọgbụgbọ, agụụ agụụ, afọ ntachi |
| Placebo | -2.1% | -0.2% | Enweghị mgbanwe dị ịrịba ama |
Nleta data (atụnyere mbelata ibu)
Chaatị mmanya na-esonụ na-egosi nke ankezi arọ mbelatagafere usoro ọgwụgwọ Retatrutide dị iche iche ma e jiri ya tụnyere placebo:
Oge nzipu: Sep-16-2025